{"filing":{"accession_number":"0001193125-26-338011","cik":"0001762303","ticker":"AVHHL","company_name":"AVITA Medical, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"rcel-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526338011/rcel-20260806.htm"},"events":[{"id":25623,"run_id":23256,"accession_number":"0001193125-26-338011","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"AVITA Medical issued a press release on August 6, 2026, announcing Q2 2026 financial results, including record revenue of $21.7 million (18% YoY growth), improved gross margins, and raised full-year 2026 revenue guidance to $86–$89 million. The disclosure includes consolidated financial statements and forward guidance, which are hallmarks of an earnings release under Item 2.02. The company also announced expectations to reach cash flow breakeven in Q4 2026, a material milestone for investor assessment.","company_name":"AVITA Medical, Inc.","ticker":"AVHHL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26506,"accession_number":"0001193125-26-338011","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AVITA Medical issued a press release on August 6, 2026, announcing Q2 2026 financial results, including record revenue of $21.7 million (18% YoY growth), improved gross margins, and raised full-year 2026 revenue guidance to $86–$89 million. The disclosure includes consolidated financial statements and forward guidance, which are hallmarks of an earnings release under Item 2.02. The company also announced expectations to reach cash flow breakeven in Q4 2026, a material milestone for investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:00.030397+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26506,"accession_number":"0001193125-26-338011","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AVITA Medical issued a press release on August 6, 2026, announcing Q2 2026 financial results, including record revenue of $21.7 million (18% YoY growth), improved gross margins, and raised full-year 2026 revenue guidance to $86–$89 million. The disclosure includes consolidated financial statements and forward guidance, which are hallmarks of an earnings release under Item 2.02. The company also announced expectations to reach cash flow breakeven in Q4 2026, a material milestone for investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:00.030397+00:00","company_name":"AVITA Medical, Inc.","ticker":"AVHHL","filing_date":"2026-08-06"}]}